Viewing nowDiopas Tablet 40 mg (Valsartan)
Valsartan 2.39mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

MFDS item code 201109818 · Approved 2011.11.09 · Insurance code 642904330
Treatment of heart failure and hypertension, and reduction of the risk of death after myocardial infarction
This medication is used to manage essential hypertension. It also helps to improve heart failure symptoms in patients with intolerance to ACE inhibitors. Moreover, it has been shown to reduce the risk of death in patients with left ventricular dysfunction or reduced contractile function following a myocardial infarction. Thus, this drug is used to protect cardiovascular health and increase patient survival rates.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, oral administration of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years and older): Initiate treatment with this medicine at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this medicine at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this medicine at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with this medicine at 40 mg once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When administering concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily; thereafter, over several weeks, the dose is increased as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering more than 80 mg daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1) Children: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This drug can cause serious harm to the fetus, especially in the second and third trimesters of pregnancy, so it should be stopped immediately upon confirmation of pregnancy. Women who are pregnant, potentially pregnant, or breastfeeding should not take this medication. It should not be administered to patients with severe liver disease, cirrhosis, biliary obstruction, or severely impaired kidney function. Patients with a history of angioedema or those who have developed angioedema while receiving ACE inhibitors or angiotensin II receptor antagonists should not use this drug. Caution should be exercised when administering to elderly patients, those with hyperkalemia, or patients with liver impairment, as dose adjustments may be necessary. Patients with heart failure, those who have had a myocardial infarction, or patients dependent on renal function require assessment of kidney function and blood pressure monitoring while taking this medication. Side effects such as hypotension, dizziness, fatigue, headache, and cough may occur during use; if symptoms are severe, consult a physician. Caution is advised when taken with potassium-sparing diuretics or potassium supplements, as blood potassium levels may become dangerously high. When used with non-steroidal anti-inflammatory drugs, the blood pressure-lowering effect may be reduced or kidney dysfunction may occur, so consultation with a healthcare professional is recommended. Because this drug lowers blood pressure, there is a risk of sudden drops in blood pressure leading to fainting or dizziness upon initial dosing, so special care is needed during the start of treatment. Patients should be cautious of the risk of accidents due to dizziness while driving or operating machinery. Regular monitoring of blood pressure, kidney function, and electrolyte levels is necessary while taking this medication, and abnormal symptoms should be reported immediately to healthcare providers. Use in children and adolescents is not recommended, as safety and efficacy have not been established. In cases of overdose, serious hypotension or loss of consciousness may occur; emergency medical attention should be sought immediately. Store in a locked location out of reach of children and avoid transferring to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. Additionally, it is important to store it in a cool place below 30 degrees Celsius to maintain its efficacy.
Yellow round oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 2.39mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.